Reducing the Burden of HPV-associated Cancer and Disease through Vaccination in the US
ShareCompartir
On This Page
Tuesday, February 19, 2013, at 1 p.m. – 2 p.m., EST
This session of Grand Rounds explored the burden of human papillomavirus (HPV) -associated cancer and disease in the United States and prevention through HPV vaccination.
HPV is the most common sexually transmitted infection in the United States. There are more than 40 HPV types, some of which cause cancers and others which cause genital warts. Each year, there are an estimated 26,000 HPV-attributable cancers in the United States. About 17,000 occur in women, most of which are cervical cancers, and about 9,000 occur in men, most of which are oropharyngeal cancers. CDC estimates that $8 billion are spent each year on direct medical costs for preventing and treating HPV-associated disease. Currently available HPV vaccines prevent infection from the HPV types that cause about 70% of cervical cancers and the majority of other HPV-attributable cancers. HPV vaccine has been recommended for routine vaccination of 11-12 year-old girls since 2006 and for 11-12 year-old boys since 2011.
This session also provided more insight about the HPV vaccination program and how CDC, state and local health departments, and health care providers are working together to achieve high vaccination levels and reduce the substantial burden of HPV-associated disease.
Presentation
Beyond the Data Beyond brings you “take home” messages for you to use in your practice, in your classroom and in your home.
Lauri E. Markowitz, MD highlights how providers can help:
- Send reminders to parents and patients that they need to come back for the next vaccine
- Arrange for "quick visits" – come in, get vaccine and leave – no appointment necessary
- Let parents and teens know that this is an anti-cancer vaccine – safe and effective
Presented By
Mona Saraiya, MD, MPH
CAPT, U.S. Public Health Service
Division of Cancer Prevention and Control
National Center for Chronic Disease Prevention and Health Promotion, CDC
“Public Health Importance of Human Papillomavirus Infection and Disease”
Eileen F. Dunne, MD, MPH
CAPT, U.S. Public Health Service
Epidemiology and Statistics Branch, Division of STD Prevention
National Center for HIV, Viral Hepatitis, STD and TB Prevention, CDC
“Overview of HPV Vaccines and Monitoring Vaccine Impact”
Shannon Stokley, MPH
Acting Associate Director of Science, Division of Immunization Services
National Center for Immunization and Respiratory Diseases, CDC
“US HPV Vaccination Program, Progress and Challenges”
Amy Middleman, MD, MSEd, MPH
Associate Professor and Director, Adolescent and Young Adult Immunization
Texas Children’s Hospital Center for Vaccine Awareness and Research
“What is Needed to Increase HPV Vaccine Coverage?”
Lauri E. Markowitz, MD
Team Lead, Epidemiology and Statistics Branch, Division of STD Prevention
National Center for HIV, Viral Hepatitis, STD and TB Prevention, CDC
“Looking Forward – Global and Domestic HPV Vaccination Programs”
Facilitated By
Tanja Popovic, MD, PhD, Scientific Director, Public Health Grand Rounds
John Iskander, MD, MPH, Deputy Scientific Director, Public Health Grand Rounds
Susan Laird, MSN, RN, Communications Manager, Public Health Grand Rounds
Additional Resources
- Page last reviewed: February 19, 2013
- Page last updated: February 19, 2013
- Content source:
- Centers for Disease Control and Prevention
- Page maintained by: Office of Associate Director of Communication, Division of Public Affairs